Cresco Labs (OTCMKTS:CRLBF) Lowered to “Hold” Rating by Atb Cap Markets

Atb Cap Markets lowered shares of Cresco Labs (OTCMKTS:CRLBF) from a strong-buy rating to a hold rating in a research note released on Monday,Zacks.com reports.

Several other equities research analysts also recently issued reports on the company. Cormark downgraded Cresco Labs from a “moderate buy” rating to a “hold” rating in a research note on Monday, November 11th. Needham & Company LLC restated a “hold” rating on shares of Cresco Labs in a report on Monday, August 12th. Finally, Roth Capital raised shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $2.50.

Cresco Labs Trading Down 0.0 %

Cresco Labs stock opened at $1.08 on Monday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The firm has a market cap of $524.75 million, a price-to-earnings ratio of -5.38 and a beta of 1.73. The firm’s 50 day moving average price is $1.40 and its two-hundred day moving average price is $1.58. Cresco Labs has a 1 year low of $1.02 and a 1 year high of $2.65.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.